Doxapram


Generic Medicine Info
Contraindications
Severe HTN, status asthmaticus, coronary artery disease, epilepsy and other convulsive disorders, cerebral oedema, CVA, hyperthyroidism/thyrotoxicosis, physical obstruction of the resp tract, head injury, known or suspected pulmonary embolism. Patients on mechanical ventilation.
Special Precautions
Patient w/ cerebrovascular disease, hypermetabolic states (e.g. phaeochromocytoma), HTN. Hepatic or renal impairment. Monitoring Parameters Monitor heart rate, BP, deep tendon reflexes, CNS status, ECG. Measure arterial blood gas and pH frequently during treatment.
Adverse Reactions
Significant: Dysrrhythmias, seizure, HTN or hypotension, dyspnoea. Nervous: Confusion, convulsions, dizziness, hallucinations, headache, hyperactivity. GI: Diarrhoea, nausea, vomiting. Resp: Bronchospasm, cough, hiccup, laryngospasm, hyperventilation, rebound hypoventilation. Genitourinary: Urinary retention, urinary bladder stimulation w/ spontaneous voiding. Musculoskeletal: Muscle fasciculation or spasticity. Dermatologic: Flushing, sweating, warm sensation. Others: Fever.
Drug Interactions
Additive pressor effect when concurrently used w/ MAOIs or sympathomimetics. May temporarily mask the residual effect when used w/ neuromuscular blocking agents. May cause increased CNS stimulation, agitation, muscle fasciculation and hyperactivity w/ concurrent use of aminophylline/theophylline. Cardiac arrhythmias may occur when given w/ anaesthetics that are known to sensitise the myocardium to catecholamines (e.g. enflurane, halothane, isoflurane), delay initiation of doxapram for at least 10 min after discontinuance of anaesthesia.
CIMS Class
Respiratory Stimulants
ATC Classification
R07AB01 - doxapram ; Belongs to the class of respiratory stimulants. Used in treatment of respiratory diseases.
Disclaimer: This information is independently developed by CIMS based on doxapram from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in